Analyst picks & changes

Biogen Inc.

(BGEN), Cambridge, Mass.

Business: Autoimmune/Inflammation

Hambrecht & Quist analyst Richard van den Broek said BGEN's loss of the Fiers patent in Europe has no impact on the company's ability to make and

Read the full 341 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE